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Chemokines control the migration of cells in normal physiological processes
and in the context of disease such as inflammation, autoimmunity and
cancer. Two major interactions are involved: (i) binding of chemokines to
chemokine receptors, which activates the cellular machinery required for
movement; and (ii) binding of chemokines to glycosaminoglycans (GAGs),
which facilitates the organization of chemokines into haptotactic gradients
that direct cell movement. Chemokines can bind and activate their receptors
as monomers; however, the ability to oligomerize is critical for the function
of many chemokines in vivo. Chemokine oligomerization is thought to
enhance their affinity for GAGs, and here we show that it significantly affects
the ability of chemokines to accumulate on and be retained by heparan sul-
fate (HS). We also demonstrate that several chemokines differentially rigidify
and cross-link HS, thereby affecting HS rigidity and mobility, and that HS
cross-linking is significantly enhanced by chemokine oligomerization.
These findings suggest that chemokine–GAG interactions may play more
diverse biological roles than the traditional paradigms of physical immobil-
ization and establishment of chemokine gradients; we hypothesize that they
may promote receptor-independent events such as physical re-organization
of the endothelial glycocalyx and extracellular matrix, as well as signalling
through proteoglycans to facilitate leukocyte adhesion and transmigration.1. Introduction
Glycosaminoglycans (GAGs) are long chains of repeating saccharide units that
get attached to protein cores to form proteoglycans that are either inserted into
cell membranes or secreted/shed into the extracellular matrix (ECM) [1,2]. For
example, heparan sulfate (HS) is a ubiquitous GAG found on almost all cell sur-
faces where it is attached as part of the HS proteoglycans syndecan and
glypican to the membrane and forms a large component of the endothelial gly-
cocalyx [1–3]. Along with the ECM, one function of HS and other GAGs in the
glycocalyx is to provide structural support for the physical deposition of a wide
number of growth factors, cytokines, chemokines and other ECM proteins [4].
However, more recently this layer has been described as playing a dynamic
physical role in controlling the permeability of the endothelium to leukocytes
by regulating leukocyte adhesion to the endothelial cells prior to their transmi-
gration through the endothelial cell layer [5–8]. It also physically responds to
forces such as shear stress, thereby transducing mechanical signals into cellular
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Figure 1. Structures of chemokines used in this study with major GAG-
binding residues highlighted. Different subunits of chemokines are shown
as grey and cyan ribbons. Highlighted residues (space-filling representation,
blue) are those previously identified as being important for binding to
GAGs. (a) CCL7 (PDB ID 1BO0 [34]; residues highlighted include R14, K18,
K19, K22, R24, K46, K49 [32]). (b) CXCL11 (PDB ID 1RJT [35]; residues high-
lighted include K46, K50, K52, K57, K59, R62 [36]). (c) CCL2 (PDB ID 1DOM
[37]; residues highlighted include R18, K19, R24, K49 [38]). (d ) CXCL8 (PDB
ID 1IL8 [39]; residues highlighted include H18, K20, R60, K64, K67, R68 [40]).
(e) CXCL4 (PDB ID 1RHP [41]; residues highlighted include K61, K62, K65, K66
[42]). ( f ) CCL5 (PDB ID 5CMD [43], only hexamer shown; residues highlighted
include R44, K45, R47 [44]).
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consequence of disease [10–13]. The control mechanisms
involved in physical regulation of this barrier have yet to be
fully described but are thought to be integral factors in
inflammation and cell migration [11,14,15], suggesting the
potential involvement of chemokines.
Chemokines are a family of chemotactic cytokines that
play key roles in mediating leukocyte adhesion and cell
migration [16–18]. In addition to binding and activating che-
mokine receptors on the migrating cells, chemokines bind to
GAGs, an interaction that has been demonstrated to be vital
for their function in vivo [19]. This functional requirement
has been demonstrated with GAG-binding-deficient mutants
of several chemokines (e.g. CXCL8, CXCL12, CCL2, CCL5
and CCL7) using in vivo mouse models of inflammation
where the mutants block the function of wild-type (WT) che-
mokines and/or fail to recruit immune cells [20–26]. The
importance of chemokine–GAG interactions has been attrib-
uted to the need to localize chemokines to inflammatory
environments where they are produced [27], particularly in
the presence of convective transport by flow in blood vessels
and capillaries. These interactions are also thought to be
important for the formation of haptotactic chemokine gradi-
ents that provide directional cues for migrating cells [27,28].
However, other mechanisms related to modifying the organ-
ization of GAGs on cell surfaces and the ECM may be
operative [29]. Along these lines, recent studies demonstrated
that the tumour necrosis factor-stimulated gene-6 (TSG-6)
can interconnect individual chains of hyaluronan (HA), and
thus non-covalently cross-links this GAG [30]. The functio-
nal consequence of this cross-linking was suggested to
be ‘HA-remodelling’ for regulating leukocyte adhesion and
enhancing the sequestration of additional ECM proinflamma-
tory mediators [31]. Similarly, cross-linking of HS by growth
factors such as FGF-2 as well as the chemokines CXCL12a
and g has also been demonstrated [29]. These studies
involved the use of biophysical techniques referred to as
quartz crystal microbalance with dissipation monitoring
(QCM-D) and fluorescence recovery after photobleaching
(FRAP) to report on physical properties (rigidification and
mobility, respectively) of GAG films upon protein binding.
The observation that CXCL12a cross-links HS chains by
QCM-D and FRAP is in agreement with results from surface
plasmon resonance (SPR), which revealed a dependence of
chemokine–GAG affinities on the density of the immobilized
GAG chains, in a manner suggestive of cross-linking [32,33].
The purpose of the present study was to determine
whether cross-linking of GAG chains is a common feature of
chemokine–GAG interactions, and to provide insight into the
underlying structural mechanisms. In particular, prior studies
demonstrating that HA induces oligomerization of TSG-6,
and that the TSG-6 oligomers act as cross-linkers of HA films
[30], motivated us to consider analogous mechanisms with
chemokines. Indeed, all chemokines have the same basic ter-
tiary fold (figure 1a,b; CCL7 and CXCL11, respectively), and
they generally bind and fully activate their receptors as mono-
mers [20,45–47]. However, many chemokines oligomerize,
which might facilitate bridging of individual GAG chains as
observed for TSG-6 oligomers. Chemokines from the CC sub-
family generally form ‘CC-like’ dimers through association of
N-termini (figure 1c, CCL2) while CXC chemokines generally
form ‘CXC-like’ dimers through association of b-sheets [39]
(figure 1d, CXCL8). Others form larger oligomers, such astetramers in the case of CXCL4 [41] (figure 1e) and polymers
in the case of CCL5 [43] (figure 1f). As for HA-induced oligo-
merization of TSG-6 [30], GAGs can also stabilize or induce
chemokine oligomerization [32,38]. Thus within the chemokine
family, there is a broad range of GAG affinities and oligomer-
ization propensities, as well as effects of GAGs on chemokine
oligomerization, that could contribute to chemokine specific
effects in modulating the biomechanical and structural
properties of endothelial and ECM GAGs.
In this study, we characterized six chemokines that have a
wide range of GAG-binding affinities and oligomerization
propensities, from monomers to polymers (figure 1), for their
ability to bind to and modify HS films using QCM-D
(figure 2a) and FRAP (figure 2b). We also examined oligomer-
ization-deficient chemokines to directly probe the role of
oligomerization. Our results suggest that chemokines differen-
tially accumulate on and rigidify HS films. In the case of CCL2,
CCL5 and CXCL4, we also show that HS chain modification is
dependent on their ability to oligomerize and that oligomeriza-
tion allows chemokines to cross-link HS chains over greater
distances than non-oligomerizing counterparts. These results
provide insight into the potential of chemokines to modify
the physical properties of HS chains in the ECM and the glyco-
calyx, which may reflect an important aspect of chemokine
function—modulating the ECM and endothelial cell barrier
function to facilitate leukocyte adhesion and transmigration.2. Results
2.1. Chemokines differentially bind to and rigidify
heparan sulfate films
In previous studies, we investigated the interaction of
several chemokines and oligomerization-deficient chemokine
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Figure 2. Formation of HS films on a passivated QCM-D sensor and for FRAP. Schematic of surfaces used for (a) QCM-D and (b) FRAP adapted from [29]. Formation
of (c) low- and (d ) high-density HS surfaces on a QCM-D sensor; streptavidin (1 or 20 mg ml21) was flowed over a gold-coated sensor covered with a passivation
layer presenting biotin groups until saturation was reached (224 Hz, no change in dissipation). Biotinylated HS (2 or 5 mg ml21) was then grafted onto this
surface to create a low-density HS film (27 Hz, 1.5 dissipation units) (c) or a high-density HS film (224 Hz, 4.5 dissipation units) (d ), which could then be
used to monitor interactions of HS with chemokines or mutants.
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action affinities and kinetic on/off rates as well as insight into
the relative propensity of the chemokines and their mutants
to oligomerize on HS, we observed that for some chemo-
kines, the affinities were dependent on the density of the
immobilized HS chains [32,33]. These observations led us to
hypothesize that some chemokines, particularly those that
oligomerize, might cross-link HS chains. In order to test
this hypothesis, we set out to determine if the same set of
chemokines could modify HS surfaces, possibly through
cross-linking, using QCM-D experiments. QCM-D has been
previously used to investigate cross-linking/remodelling of
HA by TSG-6 [30,48] and, more recently, HS by growth
factors FGF-2 and -9, the cytokine IFNg and chemokines
CXCL12a and CXCL12g [29,49].
In the QCM-D approach, one creates an artificial biomi-
metic surface by passivating gold-coated QCM-D sensors
with a monolayer of oligo ethylene glycol (OEG) thiols
doped with biotinylated OEG thiol. The surfaces are then
coated with a monolayer of streptavidin, followed by a mono-
layer of biotinylated HS. The resulting film presents a
monolayer of HS whose density can be controlled and inter-
actions with various GAG-binding proteins interrogated
(figure 2a). Note that in these experiments, HS is biotinylated
and then immobilized on streptavidin through its reducing
end to mimic attachment to proteoglycans and thereby mini-
mize artificial perturbations of the protein–HS interactions
under study.QCM-Dmeasures two parameters: (i) the frequency, or fre-
quency shift relative to a control (Df, in Hertz), which is
sensitive to changes in areal mass density, and therefore
reports onmolecular binding events (e.g. binding of HS, strep-
tavidin or chemokine in our study); and (ii) the dissipation, or
dissipation shift relative to a control (DD, in dissipation units,
1026), which reflects changes in the morphology of the bio-
molecular film on the sensor surface (e.g. relative softness or
rigidification). Figure 2c,d illustrates the formation of a
lower-density (27 Hz, þ1.5 dissipation units) HS surface
and a saturated (224 Hz, þ4.5 dissipation units) HS surface,
respectively, as previously described [29,49]. The resulting
HS films are soft and hydrated, as indicated by the increase
in dissipation upon HS addition [50]. The frequency shifts
upon HS binding correspond to areal HS densities of 10 and
36 ng cm22, respectively [51]. Changes in frequency and dissi-
pation upon flowing chemokine over the surface can then be
used to assess binding to and rigidification of the HS film
[49]. The frequency and dissipation corresponding to bound
HS and HS film softness, respectively, are set to zero in sub-
sequent figures (described below) to focus exclusively on the
effects of chemokine addition.
Figures 3 and 4 (black curves) demonstrate the changes in
frequency and dissipation of a saturated HS surface after WT
chemokines are flown over the surface. Several chemokines,
representative of a broad range of oligomerization propensi-
ties, were chosen for this study in order to determine the
effect of oligomerization on cross-linking HS: CCL7 (monomer
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Figure 3. CXCL8-, CCL2- and CCL7-mediated modification of high- and low-density HS films. (a) CXCL8, (b) CCL2 or (c) CCL7 (500 nM) were passed over a QCM-D sensor
displaying high-density (high HS) or low-density (low HS) HS films. Alternatively, chemokine was passed over a streptavidin-coated surface with no immobilized HS (no
HS) to check non-specific binding (passivation). Subsequent changes in the (i) frequency (a decrease indicates bound chemokine) or (ii) dissipation (a decrease indicates
HS film rigidification) as a function of time are plotted. Chemokine injection start and endpoints are indicated by arrows on each curve.
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[36]), CXCL8 (dimer [52]), CCL2 (dimer [38]), CXCL4 (tetra-
mer [41]) and CCL5 (polymer [43]). All chemokines produce
a reduction in frequency, indicative of binding to the HS surface
with the order of maximal signal change as follows: CCL5
(less than 230 Hz). CXCL4 (221+3 Hz). CCL2 (220+
1 Hz). CXCL11 (214+1 Hz)¼ CCL7 (214+1 Hz).
CXCL8 (29+1 Hz). These values indicate the level of accumu-
lation reached at equilibrium by each chemokine on the HS
surface with 500 nM chemokine in the solution phase, except
for CCL5, which showed continued binding even after pro-
longed incubation for 60 min. Because the molecular weights
of the chemokines are within 15% of each other, the values
reflect to a first approximation the relative number of bound
chemokine molecules, although their exact localization within
the HS film, and effects on the morphology of the HS film
may also affect the frequency shift. It is important to note that
the maximal accumulation is not determined exclusively
by the chemokine–HS affinity but rather affinity coupled
with the propensity of the chemokine to oligomerize; thus itis not surprising that CCL5 and CXCL4 showed the greatest
accumulation because they form polymers and tetramers,
respectively, and also have the highest apparent affinity for
HS of the chemokines tested [33]. These QCM-D experiments
also demonstrate the variable rates of chemokine dissociation
from the HS surface, where CXCL4, CXCL11 and CCL5 have
slower rates of dissociation than CXCL8, CCL2 and CCL7, con-
sistent with prior SPR kinetic data and the higher HS affinities
of the former group [33]. CXCL8 also has a notably slow rate of
association, again consistent with its relatively low affinity for
HS [33].
In addition to providing insight into relative variations in
the amount of chemokine bound to the HS films, QCM-D
also enables simultaneous monitoring of the effect of chemo-
kine binding on the rigidity of the HS surface through the
dissipation readout, DD [50]. All chemokines produced a
reduction in dissipation of the HS film indicating increased
rigidity or reduced softness. However, the magnitude of the
effect broadly distinguished two groups of chemokines.
Chemokines that had a modest maximal effect on HS film
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Figure 4. CXCL4-, CXCL11- and CCL5-mediated modification of high- and low-density HS films. (a) CXCL4, (b) CXCL11 or (c) CCL5 (500 nM) were passed over a
QCM-D sensor displaying high-density (high HS) or low-density (low HS) HS films. Alternatively, chemokine was passed over a streptavidin-coated surface with no
immobilized HS (no HS) to check non-specific binding ( passivation). Subsequent changes in the (i) frequency (a decrease indicates bound chemokine) or (ii) dis-
sipation (a decrease indicates HS film rigidification) as a function of time are plotted. Chemokine injection start and endpoints are indicated by arrows on each curve.
The frequency plot for CCL5 demonstrates some non-specific binding (reduction in frequency) to the passivated surface (no HS) that is largely absent with the other
chemokines used. This binding is associated with an increase in the dissipation on the HS-free surface, probably as a result of CCL5 polymerization, leading to a slight
distortion of the dissipation measurement.
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dissipation units), CCL7 (21.2 dissipation units) and CCL2
(21.3 dissipation units) (figure 3). The second group, which
produced larger maximal reductions in dissipation (more
than 2 dissipation units), and therefore greater HS film rigidi-
fication, includes CXCL4 (22.8 dissipation units), CXCL11
(22.4 dissipation units) and CCL5 (22.7 dissipation units)
(figure 4). After washing with buffer, dissociation of the che-
mokines from the HS film resulted in a reversal of HS film
rigidification. In the cases of CXCL8, CCL2 and CCL7, the
dissipation signal returned to pre-chemokine levels following
buffer wash due to their relatively rapid rates of dissociation
from the HS surface (figure 3). Conversely, the slower rates of
chemokine dissociation observed for CXCL4, CXCL11 and
CCL5 (figure 4) resulted in only small increases in dissipation
following buffer wash. CXCL11 demonstrated an initial rapidloss of chemokine (indicated by the increase in frequency;
figure 4b(i)), which then plateaued, and the dissipation
signal showed a similar pattern (figure 4b(ii)). Thus, modifi-
cation of the HS film softness is a direct result of
chemokine binding, the magnitude of which is chemokine
dependent. Moreover, the dissociation rates of different che-
mokines dictate the duration of the modifications, and
result in both transient and more long-lasting effects.
2.2. Chemokine-mediated effects on heparan sulfate
film rigidity are dependent on the surface density
of the heparan sulfate chains
Given our previous observations of density-dependent
chemokine–HS interactions by SPR [32,33], we investigated
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dification using QCM-D. QCM-D sensor surfaces were
functionalized as described above, but with only a third
of the amount of HS (27 Hz; ‘low-density HS surface’)
immobilized relative to the saturated HS surface (224 Hz;
‘high-density HS surface’) (figure 2) [51].
As shown in figures 3 and 4 (red curves), the low-density
HS surface results in a reduction of the maximal level of bound
chemokine, with the exception of CXCL4, with the most dra-
matic reductions observed for CXCL8, CCL2 and CCL7
compared with more moderate reductions with CXCL11 and
CCL5. Conspicuously, CXCL8, CCL2 and CCL7 produced
no reduction in dissipation in contrast with their effects on
the high-density HS surface (figure 3), indicating that the rigi-
difying effect is reduced on the low-density HS surface. In the
case of CCL2 and CCL7, the lack of measurable dissipation
shift is despite their ability to bind to the surface, as indicated
by the frequency measurements; in the case of CXCL8, very
little chemokine even bound to the low-density HS surface
(figure 3a). By contrast, CXCL4, CXCL11 and CCL5 were
able to rigidify the low-density HS film substantially as indi-
cated by the marked decrease in dissipation (figure 4). As
with the high-density surface, CCL5 and CXCL4 produced a
greater reduction in dissipation on the low-density surface
than CXCL11. Although the effects were diminished in com-
parison with the high-density HS surface, the fact that these
three chemokines could still substantially modify the low-
density HS surface suggests that they can overcome the greater
distance between HS chains and/or reduced density of HS
binding sites to effectively rigidify the film.2.3. Chemokine-mediated heparan sulfate rigidification
is facilitated by oligomerization
In our previous studies on the affinity and interaction kinetics
of chemokines with GAGs by SPR, we observed a striking
role of chemokine oligomerization through the use of
oligomerization-deficient chemokine mutants [32,33]. The
results motivated experiments to explore whether oligomeri-
zation plays a role in the observed chemokine-mediated
rigidification of HS films using QCM-D. For this purpose,
we used an E26A mutant of CCL5 (which forms tetramers)
and an E66S mutant (which forms dimers) [53] for comparison
with WT CCL5 (which forms polymers) [43]. Addition of WT
CCL5 to a high-density HS surface produced a reduction of
the dissipation measurement (22.7 dissipation units) compar-
able with the E66S dimer (22.7 dissipation units) but less than
the E26A tetramer (23 dissipation units) (figure 5a(ii)). This
lower effect of WT CCL5 may be due to the effects of non-
specifically bound protein, as described in the legend of
figure 4. The QCM-D frequency measurement also demon-
strated that the E66S dimer, and to a lesser extent the E26A
tetramer, dissociated more rapidly from HS films than WT
CCL5 following buffer wash (figure 5a(i)). On low-density
HS surfaces, WT CCL5 and the E26A tetramer had the same
maximal effect on dissipation (21 dissipation unit) while the
E66S dimer showed a reduced maximal effect (20.6 dissipa-
tion units), presumably due to a reduced level of bound
E66S dimer compared with WT CCL5 and the E26A tetramer
(figure 5b). This small E66S-mediated reduction in dissipation
was also entirely lost following buffer washing, in contrast
with the E26A tetramer. Together these data suggest thatalthough the dimeric form of CCL5 is able to rigidify the HS
chains, higher-order oligomers are necessary for maximal
binding and retention of CCL5 on the HS surface.
We also explored the role of oligomerization on CCL2-
mediated HS rigidification using a P8A mutant that forms
monomers instead of WT dimers [46]. Addition of the P8A
monomer to the high-density HS surface resulted in very
little binding at the same concentration as WT CCL2 (data
not shown); thus a sixfold higher concentration of P8A was
used to produce sufficient binding and enable comparison
with the WT chemokine (figure 5c). Despite significant
binding of P8A compared with WT CCL2, no reduction in
dissipation was achieved. This finding suggests that oligo-
merization of CCL2 is necessary to produce high-affinity
HS interactions and enable modification of HS chains, in
agreement with the previous interpretation of SPR data [32].
Finally, we compared WT CXCL4 (tetramer) and a K50E
mutant dimer to assess the effect of tetramer formation on
HS film rigidification [54]. Previous characterization of this
chemokine/mutant pair by SPR showed that dimeric K50E
has a weaker affinity for HS primarily due to a more rapid
off rate [33]. This finding was replicated here, as demon-
strated by the frequency measurements; CXCL4 showed
initial loss of bound protein followed by a levelling out,
whereas less of the K50E dimer bound, and it was continu-
ously released from the HS surface as buffer was flowed
over (figure 5d ). WT CXCL4 produced a significantly greater
rigidifying effect on high-density HS films (22.8 dissipation
units) in comparison with the K50E dimer (21.4 dissipation
units). This finding was also replicated on low-density HS
films, where K50E produced no effect on dissipation despite
the significant levels of bound protein, in contrast to WT
CXCL4 (figure 5e). These data suggest that the ability of
CXCL4 to rigidify HS chains is dependent on its ability to
form tetramers, which also promotes retention of the chemo-
kine on the HS surface. Also of note is that a reproducibly
observed discontinuity in the frequency change for binding
of WT CXCL4 to the high-density HS surface is not replicated
on the low-density surface or with the K50E mutant. The
cause of the discontinuity is unknown but seems likely to
be dependent on tetramer formation or a dimer–tetramer
equilibrium, where the nature of the interaction of CXCL4
with HS changes at a given level of bound CXCL4.
2.4. Chemokine-mediated heparan sulfate cross-linking
is a major cause of heparan sulfate film
rigidification
The QCM-D experiments described above demonstrate that
certain chemokines can increase the rigidity of HS films
and that this property is dependent on their ability to oligo-
merize. However, this assay does not directly address
whether the observed rigidification is due to cross-linking
of the HS chains (which has potential relevance to proteogly-
can clustering, and related functional effects [29,55]), or
whether the HS chains simply wrap around the chemokine.
Importantly, the HS anchor points (e.g. biotin sites) are
estimated to be 5 nm apart from each other on the high-
density surfaces, whereas on the low-density surfaces they
are approximately 9 nm apart [29,49,51]. In an earlier study,
the chain length of the bound HS was also estimated to be
20 monosaccharides or approximately 10 nm [29]. Taken
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Figure 5. The role of chemokine oligomerization in modification of high- and low-density HS films. (a,b) CCL5 polymer or its oligomerization mutants, E26A
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oligosaccharides should be able to contact each other, thereby
allowing for cross-linking [29].To address this question, we turned to FRAP to directly
examine the lateral mobility of the HS chains in the presence
and absence of chemokine. For these experiments, an HS film
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cing a lipid bilayer doped with biotinylated lipids onto a
glass slide, followed by fluorescently labelled streptavidin
and finally biotinylated HS (figure 2b) [29,49]. In this exper-
imental set-up, a slowing of the fluorescence recovery
reflects the reduced diffusion of streptavidin due to
cross-linking of the attached HS chains.
In the absence of chemokine, a diffusion rate of
1.6 mm2 s21 was measured for fluorescently labelled strepta-
vidin. Upon addition of CCL5 followed by a wash step, it
was reduced to 0.05 mm2 s21 (figures 6a and 7a). By compari-
son, CXCL11 produced a lesser, but significant, reduction in
diffusion to 1.0 mm2 s21 (figures 6b and 7b). In the case of
CXCL4, the default model with one mobile and one immobile
fraction fitted the data poorly, indicating that a more complex
situation was operative than that observed for CCL5 and
CXCL11 (which may or may not be related to the discontinu-
ity seen in the QCM-D frequency data). An extended model
with two mobile fractions with distinct diffusion coefficients
fit the data well and suggested that 78% of the film had a sig-
nificantly reduced diffusion constant (0.005 mm2 s21) and
22% had a more rapid (0.6 mm2 s21) but still significantly
reduced diffusion compared with the film in the absence of
CXCL4 (figures 6c and 7c). In all cases, guanidinium hydro-
chloride (GuaHCl) was incubated on the HS film to remove
bound chemokine and to demonstrate that this treatment
returned films to their original laterally mobile state. Thus,
it seems likely that CXCL4-, CXCL11- and CCL5-mediated
rigidification of the HS films observed in the QCM-D
experiments is due to cross-linking of the HS chains.
The HS density used in the above FRAP experiments is likely
to be comparable with the low-density HS surface used for
QCM-D [29]; thus it is not surprising that addition of CXCL8,
CCL2 or CCL7 produced no reduction of the HS diffusion
constant as detected by FRAP (figure 6d) because no reduction
in dissipation was observed in the QCM-D experiments
(figure 3). We therefore examined whether this was also the
case on a higher-density surface, where QCM-D showed a
decrease in dissipation and thus a higher degree of rigidification
than on the low-density HS films (figure 3). As indicated in
figure 6e, the high-density HS surface was characterized by a
lower starting diffusion constant (0.9 mm2 s21) compared with
the lower density HS FRAP surface (1.6 mm2 s21), probably
because of the greater density of streptavidin and the associated
HS chains. When CCL2 was incubated with this surface, fol-
lowed by buffer washing, no effect on the mobile fraction or
diffusion constant was produced, presumably due to loss of
bound protein, as suggested by rapid dissociation of CCL2 in
the QCM-D experiments. However, if the FRAP experiment
was performed without buffer washing, then CCL2 significantly
reduced the diffusion constant to 0.5 mm2 s21 (figures 6e and 7d).
This suggests that CCL2 transiently cross-links HS chains to pro-
duce the effects on rigidification seen by QCM-D. CCL7 and
CXCL8 had no effect on either the mobile fraction or diffusion
constant of these higher density HS surfaces (figure 6e), despite
the presence of bound protein (figure 3).2.5. Chemokine-mediated heparan sulfate cross-linking
is dependent on oligomerization
In order to expand our understanding of the role of chemo-
kine oligomerization in HS chain modification, we alsoexamined oligomerization-deficient mutants by FRAP. The
CCL5 E26A tetrameric mutant produced a significant
reduction of the diffusion constant (0.4 mm2 s21) compared
with the HS chains alone (1.6 mm2 s21), but the reduction
was much less than that produced by WT CCL5
(0.05 mm2 s21). No observable effect was produced by the
CCL5 E66S dimer (figures 6a and 7a). Similarly, while WT
CXCL4 produced two fractions with reduced diffusion
constants, the K50E dimer had no effect on the mobility of
the HS chains (figures 6c and 7c). Finally, in contrast to WT
CCL2 on the high-density HS FRAP experiment, the mono-
meric CCL2 mutant, P8A, had no effect on HS chain
mobility (figures 6e and 7d ). As in the QCM-D assays
(figure 5c), P8A was administered at sixfold higher concen-
tration than WT CCL2 to reach comparable degrees of
binding to the HS film. These results demonstrate that
CCL5, CXCL4 and CCL2 need to form higher-order
oligomeric structures in order to cross-link HS chains.3. Discussion
3.1. Mechanisms of chemokine-induced remodelling
of heparan sulfate
Cross-linking or clustering of HS proteoglycans is known to
have functional effects that result in glycocalyx remodelling
and changes in adhesion and barrier permeability to cells
[10,12,56], and chemokines would seem to be prime candi-
dates for initiating such a process. Prior studies suggestive
of cross-linking [29,32,33] motivated the present study to
broadly investigate this phenomenon with a panel of chemo-
kines and with biophysical methods that directly assess GAG
film rigidification and cross-linking, and to explore the role of
chemokine oligomerization.
The QCM-D experiments directly probed film rigidifica-
tion, and the results demonstrate that all chemokines
rigidify HS films, but to different extents, for different dur-
ations and probably by different structural mechanisms.
The chemokines examined in this study have a broad range
of affinities and oligomerization propensities; thus in order
to compare rigidification at comparable levels of bound
protein, a normalized representation of the data is useful
(figure 8). In this representation, the ratio of dissipation
over frequency shift (DD/2Df ) for the HS film, bare or
with chemokines, is a relative measure of film softness [50],
and the negative frequency shift (2Df ) is a relative measure
of the amount of bound protein. As illustrated in figure 8a,
the six WT chemokines studied here show only minor differ-
ences in their ability to rigidify the HS surfaces (i.e. decrease
film softness) when compared at similar load levels (2Df ),
with the expected trend of CCL5, CXCL4 and CXCL11 show-
ing greater rigidification than CCL2, CCL7 and CXCL8. For
completeness, this plot also includes data for CXCL12a,
which was investigated in a previous study [29]. The com-
parison indicates that CXCL12a is at least as potent as
CCL5, CXCL4 and CXCL11 in rigidifying HS films at com-
parable protein load, a finding that is consistent with
CXCL12a also being a very potent HS cross-linker [29].
From figure 8a, it is also clear that given sufficient levels of
protein, all chemokines can rigidify the films to some
degree. However, in general, the chemokines with the highest
affinity for HS (CCL5, CXCL4 and CXCL11 [33]) showed the
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Figure 6. Chemokines cross-link HS chains dependent on oligomerization; quantitative FRAP analysis. (a) CCL5 polymer or its oligomerization mutants, E26A tetra-
mer or E66S dimer (500 nM), (b) CXCL11 (500 nM), (c) CXCL4 tetramer or its oligomerization mutant, K50E dimer (500 nM), (d ) CXCL8, CCL2 or CCL7 (500 nM) were
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Figure 7. Chemokines cross-link HS chains dependent on oligomerization; representative FRAP micrographs. (a) CCL5 or its oligomerization mutants, E26A tetramer
or E66S dimer (500 nM), (b) CXCL11 (500 nM), (c) CXCL4 or its oligomerization mutant, K50E dimer (500 nM) or (d ) CCL2 (500 nM) or its oligomerization mutant,
P8A monomer (3 mM) were incubated on a lipid bilayer supporting fluorescently labelled streptavidin to which HS chains were attached. Following bleaching and
recovery analysis, images of the bleached spot were taken to provide visual assessment of the extent of maximal bleaching (0 s, images shown for WT chemokines
only) and recovery from bleaching after 300 s (representative of two experiments).
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level (cf. minimal DD/2Df values reached in figure 8a) and
also to remain stably associated with the HS films despite
prolonged washing (cf. figures 3 and 4).
FRAP experiments were used to probe the lateral mobility
of HS chains as an indicator of HS cross-linking. These results
demonstrate that CCL5, CXCL4, CXCL11 and, to a lesser
extent, CCL2 reduce the lateral mobility of HS chains,
whereas CXCL8 and CCL7 have no effect at all. Clearly, HS
cross-linking would be expected to contribute to HS film
rigidification, but the distinct trends in the normalized rep-
resentation of the QCM-D data (figure 8) and the FRAP
data (figure 6) also imply that additional mechanisms of
film rigidification must be at play. Possible mechanisms
include HS chains individually wrapping around chemo-
kines, or simply the crowding of the HS film by chemokines.
The ability of CXCL4 and CCL5 to oligomerize is clearly
important not only for their affinity and slow off rates from
GAGs, but also for their ability to rigidify and cross-link HS
films. This was demonstrated with dimeric and tetrameric
mutants of polymeric WT CCL5, both of which showed a
reduced capacity to rigidify and remain stably associated
with HS films (figure 5a,b); moreover, the E26A tetramer
showed a reduced ability to cross-link the films relative to
WT, while the E66S dimer showed no cross-linking under
the conditions tested (figure 6a). Similarly, the CXCL4 K50E
dimeric mutant showed a reduced capacity to bind, to
remain associated with and to rigidify HS films compared
with WT tetrameric CXCL4 (figure 5d,e), and it also lost theability to cross-link HS (figure 6c). CCL5 and CXCL4 have
relatively extensive GAG-binding epitopes in the context of
their polymeric [43] (figure 1f ) and tetrameric [41] (figure 1e)
structures, respectively, which would facilitate their affinity
for, retention on and ability to cross-link HS chains.
In the case of CXCL4, normalized softness plots also
suggest that the WT chemokine is more effective in rigidify-
ing HS films than the oligomerization-impaired mutant,
even at equivalent levels of bound protein (figure 8b). It is
notable that this is not so for CCL5, as the curves for the
WT and mutant forms overlap closely (figure 8c). The com-
parable capacity of WT and mutant CCL5 to rigidify HS
films when considered on a per molecule basis contrasts
with their differential abilities to slow down HS diffusion
(cf. figures 6 and 7). A possible explanation is that dimers, tet-
ramers and polymers of CCL5 can all cross-link HS chains,
but that the stability of the cross-links increases with oligo-
mer size. In this scenario, the two HS binding patches per
CCL5 dimer (figure 1f ) bind two distinct HS chains, thus
promoting film rigidification, but such cross-links are too
short-lived to slow HS diffusion appreciably; larger oligo-
mers enhance binding to the individual HS chains, and
thus stabilize the cross-link and effectively slow HS diffusion.
The example of CCL5 thus illustrates that chemokine oligo-
merization can differentially modulate the rigidification of
HS matrices and the mobility of HS chains.
CXCL11 was also able to rigidify and cross-link HS films,
although not as robustly as CXCL4 and CCL5 (figures 4
and 6a–c). The CXCL11 structure was solved as a monomer
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Figure 8. Chemokines and oligomerization mutants differentially modify HS film softness. In order to assess HS film modification as a function of bound chemokine,
a measure of softness (DD/(2Df )) is plotted as a function of bound chemokine (2Df ) on low- or high-density HS films for (a) WT chemokines, (b) CXCL4 or its
oligomerization mutant, K50E dimer (500 nM), (c) CCL5 or its oligomerization mutants, E26A tetramer or E66S dimer (500 nM) or (d ) CCL2 (500 nM) or its oli-
gomerization mutant P8A monomer (3 mM). These curves were constructed using the same frequency and dissipation data plotted in figures 3–5. Data for
CXCL12a were added in (a) for comparison, reproduced from fig. 4b in [29] but offset along the x-axis to adjust for the slightly higher HS surface densities
used in that work.
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low pH (pH 4.5), which generally destabilizes or dissociates
chemokine into monomers or smaller oligomers [35]. At pH
5.6, however, NMR diffusion experiments indicate that
CXCL11 forms weak dimers [36]. Dimers are also consistent
with the level of accumulation of CXCL11 on heparin andHS as observed by SPR data, when compared with other che-
mokines of known oligomerization states and affinities [33];
thus we predict that dimerization is important for its HS
modifying capacity, which would make for a rather extended
GAG-binding surface (figure 1b). Several studies have also
shown that chemokines oligomerize on GAGs and that GAGs
hydrated
adhesion-resistant
glycocalyx
(a) (b) (c)
cell
membrane
protein core,
e.g. syndecan-4
signalling
glycosaminoglycan,
e.g. heparan sulfate
chemokine,
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adhesion molecules,
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chemokine-mediated
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Figure 9. Chemokine-mediated GAG cross-linking may enable syndecan clustering and manipulation of glycocalyx structure to enable leukocyte migration events.
(a) In the absence of chemokine, proteoglycans form a hydrated adhesion-resistant surface on the endothelium to control leukocyte movement. (b) Chemokine-
mediated HS cross-linking may produce syndecan clustering, enabling subsequent signalling events. (c) Chemokine-mediated HS cross-linking may restructure the
glycocalyx exposing endothelial adhesion molecules to circulating leukocytes. These potential chemokine functions could help describe the fundamental importance
of chemokine–GAG interactions.
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merization and GAG binding are thermodynamically coupled.
Among the chemokines studied here, CXCL11 may represent a
typical chemokine whose oligomerization is weak in solution
but strongly promoted upon binding to HS.
CXCL8 and CCL2 form stable dimers in solution
(figure 1c,d) [39,57]; however, because of their reduced affinity
for GAGs [32,33], they are less efficient in modifying HS com-
pared with CCL5, CXCL4 and CXCL11. CXCL8 has the lowest
affinity for HS of all the chemokines examined in this study
[33] and it showed no ability to cross-link HS chains
(figure 6d,e). CCL2 did cross-link HS, although only transi-
ently and only on high-density HS films (figure 6d,e). Similar
to CCL5 and CXCL4, CCL2-mediated rigidification and
cross-linking was dependent on oligomerization as monomeric
P8A [46] was ineffective, even at a sixfold higher concentration
than that used for the other chemokines (figures 5c and 6e). It
was also inefficient in rigidifying high-density films, and nor-
malized softness plots indicated that WT CCL2 was more
effective than P8A in rigidifying the films on a per molecule
basis (figure 8d). The fact that CCL2 requires oligomerization
to rigidify and cross-link HS films makes intuitive sense given
the position of its single GAG-binding epitope at opposite
ends of the dimer (figure 1c).
CCL7 is a monomeric chemokine [34], and thus the fact
that it did not cross-link HS (figure 6d,e) was unsurprising.
However, it was much more effective in rigidifying the HS
surfaces than the highly homologous CCL2 monomer P8A
[46] (figures 3c and 5c). The inability of CCL7 to cross-link
may be due to an inability to span epitopes between adja-
cent HS chains coupled with a slightly reduced affinity for
HS compared with WT CCL2 [32]. The ability of CCL7 to
rigidify HS films compared with P8A is consistent with its
slightly higher affinity for HS than P8A, although even on
a normalized per molecule basis, CCL7 has a greater ability
to rigidify HS (figure 8a,d). As suggested previously [32],
this is probably because CCL7 has a more dense and
extended GAG-binding surface in the context of its tertiary
structure compared with a single subunit of CCL2
(figure 1a,c). As it does not cross-link HS chains according
to the FRAP data, its ability to rigidify HS may reflect con-
densation or wrapping of individual HS chains around a
single CCL7 subunit.Taken together with information on the presence and dis-
tribution of the GAG-binding epitopes on these chemokines
(figure 1), the results suggest that oligomerization enhances
the ability of chemokines to modify HS films by a number
of inter-related factors: (i) enhanced affinity and accumu-
lation on HS due to the simultaneous binding of multiple
chemokine epitopes to HS; (ii) the ability to bridge gaps
between GAG chains by producing structures with multiple,
spatially separated GAG-binding sites such that the oligomer
can bind to multiple HS chains at once; and (iii) the ability of
multiple GAG-binding epitopes in the context of oligomers to
promote chemokine rebinding. Not surprisingly, the length
of the HS chain also influences cross-linking, with longer
chains promoting higher affinity interactions [58] and greater
rigidification than short-chain GAGs (e.g. dp6), as previously
demonstrated for CXCL12a [29]. Furthermore, it seems likely
that HS overall sulfation and fine structure will also play key
roles in promoting cross-linking given their importance in
chemokine–GAG interactions [33]. The results also suggest
that the magnitude and duration of HS rigidification and
cross-linking is specific to individual chemokines, reflecting
fine tuning of individual chemokine functions; this adds
more evidence to the idea that chemokine function may not
be as redundant as initially surmised based on the apparent
promiscuity of receptor–chemokine interactions [59].3.2. Functional consequences of heparan sulfate
rigidification and cross-linking
Chemokine–GAG interactions have been hypothesized to
provide a mechanism for chemokine localization and
formation of gradients that guide migrating cells to inflam-
matory sites [27,28]. Our data certainly support the idea
that these interactions promote the retention and slow release
of high affinity HS-binding chemokines that in turn may con-
tribute to gradient formation. However, it is also possible that
chemokine–GAG interactions are involved in structural
modification of the endothelial glycocalyx, and possibly pro-
teoglycan-dependent signalling (figure 9). This would be
consistent with an emerging view that inflammatory cyto-
kines remodel the ECM and endothelial cell glycocalyx
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barrier permeability [10,12,29,56].
The endothelial glycocalyx, which is rich in HS-contain-
ing proteoglycans, has been described as a thick adhesion-
resistant barrier to cell migration by imposing a physical
layer, estimated as being 0.2–2 mm thick [6–8]. This depth
has been suggested to inhibit accessibility to key molecules
(e.g. selectins, integrins) involved in adhesion of leukocytes
to the endothelium, an important step in transmigration [5].
Indeed a theoretical study suggested that the combination
of intact glycocalyx structure and blood flow render it imper-
vious to penetration by leukocyte microvilli [60]. Thus,
modification of this structure would be necessary for initial
adhesion events and subsequent transmigration. Tumour
necrosis factor (TNF) stimulation of the endothelium has
been shown to reduce the glycocalyx thickness and lead to
enhanced cell adhesion due to the breakdown of this physical
barrier [56]. Conversely, therapeutic protection of the glyco-
calyx structure reduces leukocyte adhesion following
ischaemia/reperfusion [61] and has been described as a
potentially wide-ranging therapeutic approach [11]. Mechan-
isms for TNF-mediated glycocalyx remodelling and
permeability were proposed to involve production of pro-
teases and proteoglycan shedding [10,12,56] and this has
been shown to be the case for TNF-a-induced disruption of
the glomerular endothelial glycocalyx [62], a process that
can be inhibited by hydrocortisone and antithrombin [63].
Chemokines may be able to modulate the glycocalyx in
similar ways. Chemokine cross-linking of HS chains,
described here in vitro, may produce a reduced thickness
and/or permeability of the glycocalyx layer in vivo. This
would represent a novel function of chemokines where, prior
to their established function in G protein-coupled receptor
(GPCR) signalling and activation of leukocytes, they phys-
ically reorganize specific sites on the endothelial surface to
mediate localized adhesion events. Importantly, CXCL12
andCCL5 have been reported to promote clustering of the pro-
teoglycans syndecan-1 and -4 onHeLa cells [64,65], whichmay
be a consequence of their ability to cross-link GAG chains as
shown here. Syndecan-4 is a particularly logical player in the
function of chemokines as one of its well-studied functions is
in the formation of focal adhesions, which are important for
cellmigration [66]. The function of syndecan-4 has been associ-
atedwith its ability to form clusters [55,67], wheremultiple HS
side chains are necessary for cell adhesion unless rescued by
antibody-induced clustering [68]. Furthermore, antibody-
mediated syndecan-4 clustering has been shown to induce
migration of endothelial cells [69]. These data suggest that
HS cross-linking and subsequent clustering by ligands could
be important in the behaviour of this proteoglycan in the con-
text of chemokines as well. CCL5 and CXCL12 have also been
shown to accelerate shedding of syndecans from the surface of
cells [70,71], which again may be linked to HS cross-linking
and proteoglycan clustering. In the case of CXCL12, the pro-
cess was shown to be dependent on proteoglycans, but not
on the CXCL12 cell surface receptor, CXCR4 [70], whereas in
the case of CCL5, it was dependent on both syndecans and
the receptor CCR5 [71].
In addition to affecting the physical structure of the
glycocalyx, receptor-independent signalling of chemokines
through proteoglycans has been observed for CXCL12
and CCL5 [65,70,72,73], and indeed, ligand-mediated cluster-
ing of syndecans appears to be a key mechanism forproteoglycan signalling [67]. For example, CCL5-mediated
signalling through the mitogen-activated protein kinase
pathway is dependent on the presence of GAGs and also
upon its ability to oligomerize [72], reflecting a potential role
for HS cross-linking. More generally, clustering of syndecan-
4 serves to concentrate the proteoglycan into micro-domains
that recruit and scaffold signalling molecules on the inside of
the cell [66], and the ability of chemokines to oligomerize
could be relevant in promoting this function. AsHS chain den-
sity also affects binding of chemokines on the outside of the
cell, the interaction between chemokines and HS may serve
to synergistically concentrate chemokines and other cytokines
on the cell surface. Overall, there are many reasons to expect
that chemokine–GAG interactions play a more elaborate role
in the overall process of cell migration than simply serving
as the stationary beacons for migrating cells (figure 9).
In conclusion, here we extend a previous observation that
CXCL12 can modify HS films to include other chemokines sep-
arated into a lower modifying group (CXCL8, CCL2 and CCL7)
and a higher modifying group (CXCL4, CXCL11 and CCL5).
The relative potency is linked to the ability of the chemokines
to oligomerize coupled with their affinity for HS. The biological
functionof this behaviour remains tobedefined; however, itmay
enable chemokines to cluster proteoglycans with concomitant
effects on proteoglycan signalling. Furthermore, remodelling of
the glycocalyx by cross-linking GAGs may represent an
additional function related to the importance of chemokine–
GAG interactions during leukocyte migration in vivo.4. Experimental procedures
4.1. Materials
Chemokines and mutants were recombinantly expressed and
purified as described previously [32,74,75]. Streptavidin and
fluorescently labelled streptavidin (Sigma Aldrich), dioleoylpho-
sphatidylcholine (DOPC), dioleoylphosphatidylethanolamine-
CAP-biotin (DOPE-CAP-biotin) (Avanti Polar Lipids, Alabaster,
AL, USA) were purchased. HS from porcine intestinal mucosa
was kindly provided by H. Lortat-Jacob (Institut de Biologie
Structurale, Universite´ Grenoble Alpes, Grenoble, France) and
biotinylated as described previously [51]. The HS was found
to have an average molecular weight of 12 kDa, a polydispersity
of 1.6 and an average of 1.4 sulfates per disaccharide [76].
4.2. Quartz crystal microbalance with dissipation
monitoring
QCM-D experiments were performed using a Q-Sense E4
system (Biolin Scientific, Va¨stra Fro¨lunda, Sweden) as pre-
viously described in detail [29,49]. Briefly, gold-coated
sensors (QSX301; Biolin Scientific) were treated in an UV/
ozone chamber for 30 min and then coated overnight by
immersion in OEG disulfide and biotinylated OEG thiol
(1000 : 1 molar thiol equivalents, 1 mM total concentration)
dissolved in ethanol. Sensors were then rinsed with ethanol
to remove any residual reagent and mounted into QCM-D
Flow Modules (Biolin Scientific) before equilibration in
running buffer (10 mM HEPES, 150 mM NaCl, pH 7.4).
Streptavidin was then grafted onto the sensor surface by
being passed over in running buffer, first at 1 mg ml21 to con-
firm no depletion from bulk flow (i.e. due to binding to the
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uration was reached (typically 224 Hz). Subsequently,
immobilization of biotinylated HS was performed by flowing
a 2 mg ml21 or 5 mg ml21 suspension in running buffer over
the sensor surface until a lower HS density (27+1 Hz;
‘low-density HS surface’) or until saturation (224+1 Hz;
‘high-density HS surface’) was reached, respectively. Chemo-
kine or chemokine mutants (typically 500 nM) were then
passed over these surfaces in running buffer and the fre-
quency and dissipation changes monitored. This
concentration was chosen in order to elicit modifying effects
on this biomimetic HS film. It is hard to compare this to rel-
evant chemokine concentrations in vivo as the effect of ECM
interactions is likely to generate a high, and currently non-
defined, localized chemokine concentration within the glyco-
calyx and tissues. Surfaces were regenerated by removing
bound chemokine (a maximum of three times) using 2 M
GuaHCl in ultrapure water which returned the frequency
and dissipation to pre-chemokine levels and had no detri-
mental effect on subsequent chemokine binding (as
demonstrated previously [49]). Data are presented as normal-
ized shifts in the resonance frequency, Df ¼ Dfn/n (n being
the overtone number), and shifts in the dissipation, DD,
obtained from the fifth overtone of the QCM-D sensor in
each instance. Any other tone (n ¼ 3, 5, . . . , 13) would have
provided similar results. Measurements were repeated twice
and data displayed are representative of these independent
experiments.
4.3. Fluorescence recovery after photobleaching
FRAP experiments were undertaken as described previously
[29]. Small unilamellar vesicles (SUVs, 100 mg ml21 total
lipid) were prepared by sonication [77] in FRAP buffer
(10 mM Hepes, 150 mM NaCl, pH 7.4) supplemented with
2 mM CaCl2. SUVs containing 99.5 mol% DOPC and
0.5 mol% DOPE-CAP-biotin (for low-density HS surfaces),
or 95 mol% DOPC and 5 mol% DOPE-CAP-biotin (for
high-density HS surfaces) were incubated (30 min, room
temperature) in wells formed on a pre-conditioned glass
slide to create a biotinylated supported lipid bilayer in situ.
Fluorescently labelled streptavidin (10 mg ml21 in FRAP
buffer) was then grafted onto the surface by incubating for20 min at room temperature, followed by washing (two
times with FRAP buffer). Biotinylated HS (10 mg ml21 in
FRAP buffer) was subsequently added and incubated for
30 min at room temperature. Chemokine or chemokine
mutants were then incubated (typically 500 nM in FRAP
buffer) with the HS film for 20 min at room temperature
prior to the FRAP experiments. GuaHCl in ultrapure water
was incubated on the HS film to remove bound chemokine
and demonstrate that this returned films to their original lat-
erally mobile state. FRAP experiments were performed using
a confocal microscope (LSM 510; Zeiss, Oberkochen,
Germany), with or without washing of the HS film with
FRAP buffer. For recovery analysis, a series of images of
the bleached spot were taken during the recovery period
(approx. 5 min). The images were then analysed using
‘time-resolved profile analysis’, a custom-made MATLAB
(MathWorks, MA, USA) protocol [29,78]. By default, a lateral
diffusion model with one mobile fraction and one immobile
fraction was used and found to fit most of the data well.
Where this was not the case, an extended model was used
featuring two mobile fractions, each with a distinct diffusion
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